A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)

Trial Profile

A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms KEYNOTE-348
  • Sponsors Amgen
  • Most Recent Events

    • 14 Dec 2017 Planned End Date changed from 4 Dec 2024 to 7 Jan 2025.
    • 14 Dec 2017 Planned primary completion date changed from 17 Feb 2021 to 23 Mar 2021.
    • 14 Dec 2017 Planned initiation date changed from 31 Jan 2018 to 2 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top